NEW YORK (GenomeWeb) – Bruker reported after the close of the market on Thursday that its fourth quarter revenues declined 8 percent year over year as currency effects negatively impacted revenues by more than 6 percent. 

For the three months ended Dec. 31, 2014, the company reported revenues of $508 million, down from $552.1 million in Q4 2013. The results were short of the average analysts' estimate of $515.5 million. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.